Relative environmental and social disadvantage in patients with idiopathic pulmonary fibrosis.
-
2022/12/01
-
File Language:
English
Details
-
Personal Author:
-
Description:Background: Air pollution exposure is associated with disease severity, progression and mortality in patients with idiopathic pulmonary fibrosis (IPF). Combined impacts of environmental and socioeconomic factors on outcomes in patients with IPF are unknown. The objectives of this study were to characterise the relationships between relative environmental and social disadvantage with clinical outcomes in patients with IPF. Methods: Patients with IPF were identified from a longitudinal database at University of California, San Francisco. Residential addresses were geocoded and linked to the CalEnviroScreen 3.0 (CES), a tool that quantifies environmental burden in California communities, combining population, environmental and pollution vulnerability into individual and composite scores (higher scores indicating greater disadvantage). Unadjusted and adjusted linear and logistic regression and Fine and Gray proportional hazards models were used. Results: 603 patients were included. Higher CES was associated with lower baseline forced vital capacity (beta=-0.073, 95% CI -0.13 to -0.02; p=0.006) and diffusion capacity of the lung for carbon monoxide (beta=-0.11, 95% CI -0.16 to -0.06; p<0.001). Patients in the highest population vulnerability quartile were less likely to be on antifibrotic therapy (OR=0.33; 95% CI 0.18 to 0.60; p=0.001) at time of enrolment, compared with those in the lowest quartile. An association between CES and mortality was suggested, but sensitivity analyses demonstrated inconsistent results. Relative disadvantage of the study cohort appeared lower compared with the general population. Conclusions: Higher environmental exposures and vulnerability were associated with lower baseline lung function and lower antifibrotic use, suggesting that relative socioenvironmental disadvantage has meaningful impacts on patients with IPF. [Description provided by NIOSH]
-
Subjects:
-
Keywords:
-
ISSN:0040-6376
-
Document Type:
-
Funding:
-
Genre:
-
Place as Subject:
-
CIO:
-
Topic:
-
Location:
-
Volume:77
-
Issue:12
-
NIOSHTIC Number:nn:20065514
-
Citation:Thorax 2022 Dec; 77(12):1237-1242
-
Contact Point Address:Dr Kerri A Johannson, Department of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada
-
Email:kerri.johannson@ahs.ca
-
Federal Fiscal Year:2023
-
Performing Organization:University of California, Berkeley
-
Peer Reviewed:True
-
Start Date:20050701
-
Source Full Name:Thorax
-
End Date:20250630
-
Collection(s):
-
Main Document Checksum:urn:sha-512:0e6a6bc49e359f5ecc7099576f4a972eee6a8f0c0f9c07b9f1036f48c80dcfc8ab3cd5da2ab02330113013c33c5657a8f8fb7508d070d6f4a5bfa03e3e1db97c
-
Download URL:
-
File Type:
File Language:
English
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like